2022---eli-lilly-and-company--goldman-sachs-maintains-its-neutral-opinion

The maintenance of the Neutral stance did little to dampen investor enthusiasm in the long term. While the rating suggested a lack of immediate "buy" urgency from the bank's perspective, Eli Lilly finished 2022 as one of the best-performing large-cap pharmaceutical companies, setting the stage for its continued ascent in the years that followed.

Concerns that the stock had become a "crowded trade," making it vulnerable to any minor earnings misses or clinical setbacks. Market Impact The maintenance of the Neutral stance did little

However, despite these strong fundamentals, Goldman Sachs analysts opted for a outlook. The primary rationale centered on "valuation discipline." At various points in 2022, Eli Lilly’s stock traded at a significant premium compared to its peers in the S&P 500 Healthcare Sector , leading analysts to suggest that much of the near-term growth was already priced into the shares. Pipeline Successes and Challenges Market Impact However